Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

US accounts for 72.7% of the MSCI World Index, compared with just 2.6% for Europe’s biggest stock market, France ...

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long ...

The Trump administration struck a new deal with Eli Lilly to offer the drug maker’s weight loss drug to some Medicare ...